AR126052A1 - Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos - Google Patents

Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos

Info

Publication number
AR126052A1
AR126052A1 ARP220101454A ARP220101454A AR126052A1 AR 126052 A1 AR126052 A1 AR 126052A1 AR P220101454 A ARP220101454 A AR P220101454A AR P220101454 A ARP220101454 A AR P220101454A AR 126052 A1 AR126052 A1 AR 126052A1
Authority
AR
Argentina
Prior art keywords
compound
formula
tautomers
prodrugs
solvates
Prior art date
Application number
ARP220101454A
Other languages
English (en)
Spanish (es)
Inventor
Simone Bonazzi
Artiom Cernijenko
Jennifer Stroka Cobb
Janetta Dewhurst
John Ryan Kerrigan
Gary Obrien
Mooje Sung
Noel Marie Thomsen
- Ting Pamela Yf France
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR126052A1 publication Critical patent/AR126052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP220101454A 2021-06-03 2022-06-01 Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos AR126052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03

Publications (1)

Publication Number Publication Date
AR126052A1 true AR126052A1 (es) 2023-09-06

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101454A AR126052A1 (es) 2021-06-03 2022-06-01 Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos

Country Status (22)

Country Link
US (2) US12103919B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520654A (cg-RX-API-DMAC7.html)
KR (1) KR20240013812A (cg-RX-API-DMAC7.html)
CN (1) CN117062811A (cg-RX-API-DMAC7.html)
AR (1) AR126052A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022284366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215410A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000013A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230614A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000261A (cg-RX-API-DMAC7.html)
EC (1) ECSP24000004A (cg-RX-API-DMAC7.html)
IL (1) IL308094A (cg-RX-API-DMAC7.html)
JO (1) JOP20230308A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014327A (cg-RX-API-DMAC7.html)
PE (1) PE20240657A1 (cg-RX-API-DMAC7.html)
PY (1) PY2243958A (cg-RX-API-DMAC7.html)
TW (1) TW202306570A (cg-RX-API-DMAC7.html)
UY (1) UY39796A (cg-RX-API-DMAC7.html)
WO (1) WO2022254362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250114A1 (es) 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
TW202604526A (zh) * 2024-04-29 2026-02-01 美商必治妥美雅史谷比公司 化合物及其治療血色素病變之用途
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
WO2026002044A1 (zh) * 2024-06-25 2026-01-02 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CN113490495B (zh) * 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
JP7874541B2 (ja) 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
MX2022004526A (es) * 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Also Published As

Publication number Publication date
WO2022254362A1 (en) 2022-12-08
US20250026736A1 (en) 2025-01-23
CN117062811A (zh) 2023-11-14
TW202306570A (zh) 2023-02-16
BR112023024905A2 (pt) 2024-02-20
ECSP24000004A (es) 2024-02-29
KR20240013812A (ko) 2024-01-30
PY2243958A (es) 2023-01-20
EP4347580A1 (en) 2024-04-10
MX2023014327A (es) 2023-12-13
CL2023003561A1 (es) 2024-06-28
AU2022284366A1 (en) 2023-10-26
UY39796A (es) 2023-07-31
US20230019617A1 (en) 2023-01-19
PE20240657A1 (es) 2024-04-04
CR20230614A (es) 2024-02-01
CO2024000013A2 (es) 2024-01-25
JOP20230308A1 (ar) 2023-11-29
JP2024520654A (ja) 2024-05-24
US12103919B2 (en) 2024-10-01
IL308094A (en) 2023-12-01
CA3215410A1 (en) 2022-12-08
DOP2023000261A (es) 2023-12-29

Similar Documents

Publication Publication Date Title
CO2022008243A2 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
CL2023003561A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos
NI201100137A (es) Derivados de sulfonamida
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ECSP23076800A (es) Derivados de pirazolopiridina y sus usos
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
AR062402A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel
ECSP077185A (es) Derivados de piridina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
PE20151607A1 (es) Formulaciones de compuestos organicos
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
UY40282A (es) Compuestos amido-heteroaromáticos
ECSP21037191A (es) Pirazoles como moduladores de la hemoglobina
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
UY27673A1 (es) Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp,
JP2013525342A5 (cg-RX-API-DMAC7.html)
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
UY27855A1 (es) Compuestos quimicos
UY29256A1 (es) Uso de deirvados de acido ciclopropanoico sustituidos para producir medicamentos para tratar el síndrome metabólico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal